New combo therapy aims to boost survival in advanced cervical cancer

NCT ID NCT06416696

Ongoing Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing whether adding the immunotherapy drug toripalimab to standard chemoradiotherapy can improve outcomes for patients with high-risk locally advanced cervical cancer. About 57 participants will receive the combination, followed by maintenance toripalimab. The main goal is to see if this approach increases the two-year survival rate without the cancer progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Toripalimab (a PD-1 inhibitor) combined with cisplatin chemotherapy and radiation therapy
What this could lead to: If successful, this could offer a more effective treatment option for high-risk cervical cancer patients, potentially improving survival rates and making therapy more accessible.
What could go wrong: This is a small, early-phase (phase II) study with only 57 participants, so results may not apply to everyone. Side effects from the drug combination are possible, and the trial is not yet complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCERS

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.